ahlam1399
03-29-2016, 04:33 PM
Keryx says anemia drug succeeds in study of kidney patients
(Reuters) - Keryx Biopharmaceuticals Inc on Tuesday said its drug to treat iron deficiency anemia in chronic kidney disease patients **t yet requiring dialysis met the goals of a late stage clinical trial, potentially paving the way for an expanded approval of the treatment.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e9333f4/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=xVFzgGlOtso:HGM6nfWFc0M:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=xVFzgGlOtso:HGM6nfWFc0M:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=xVFzgGlOtso:HGM6nfWFc0M:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=xVFzgGlOtso:HGM6nfWFc0M:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=xVFzgGlOtso:HGM6nfWFc0M:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/xVFzgGlOtso
(Reuters) - Keryx Biopharmaceuticals Inc on Tuesday said its drug to treat iron deficiency anemia in chronic kidney disease patients **t yet requiring dialysis met the goals of a late stage clinical trial, potentially paving the way for an expanded approval of the treatment.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e9333f4/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=xVFzgGlOtso:HGM6nfWFc0M:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=xVFzgGlOtso:HGM6nfWFc0M:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=xVFzgGlOtso:HGM6nfWFc0M:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=xVFzgGlOtso:HGM6nfWFc0M:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=xVFzgGlOtso:HGM6nfWFc0M:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/xVFzgGlOtso